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Abstract29
Phenytoin is an antiepileptic drug used in the management of partial and tonic-clonic30
seizures. In previous studies we have shown that valproate, another antiepileptic drug,31
reduced the amount of two key bone proteins, pro-collagen I and osteonectin (SPARC, BM-32
40), in both skin fibroblasts and cultured osteoblast-like cells. Here we show that phenytoin33
also reduces pro-collagen I production in osteoblast-like cells, but does not appear to cause a34
decrease in osteonectin message or protein production. Instead, a 24h exposure to a clinically35
relevant concentration of phenytoin resulted in a dose-dependent change in electrophoretic36
mobility of osteonectin, which was suggestive of a change in post-translational modification37
status. The perturbation of these important bone proteins could be one of the mechanisms to38
explain the bone loss that has been reported following long-term treatment with phenytoin.39
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1. Introduction50
3Many of the most commonly used anti-epileptic drugs (AEDs) are associated with51
bone disease, as evidenced by biochemical abnormalities, increased fracture risk and52
decreased bone mineral density (reviewed by Nakken and Taubøll (2010) and Lee et al.,53
2010). AEDs that are implicated in hepatic cytochrome p450 dysregulation leading to vitamin54
D deficiency with subsequent bone loss appear to have the strongest association with bone55
abnormalities (Välimäki et al., 1994 and Pack 2001). This association does not fully explain56
the mechanism(s) of AED-induced bone loss however, since an increase in bone turnover57
with AEDs can occur independently of vitamin D deficiency (Valimaki et al., 1994, and58
Weinstein 1984).59
Despite the clear body of evidence that describes the effects of AEDs on fracture risk60
and bone mass, few studies have investigated the direct effect of AEDs on bone cells. In a61
previous study, we examined the effect of the AED, valproate, on an established cell-based62
model of long bone-derived osteoblasts (hFOB1.19) and found for the first time that63
valproate reduced the amount of two key bone proteins, collagen I and osteonectin64
(Humphrey et al., 2013). Collagen I is the main protein component of bone matrix and65
osteonectin has a major role in bone development and mineralisation (Delany et al., 2003), so66
reduced levels may contribute to bone loss following long-term treatment with valproate. The67
aim of this study was to determine whether other commonly used AEDs also reduce levels of68
these important bone proteins in osteoblast-like cells.69
70
71
2. Materials and Methods72
73
2.1 AED compounds74
4AEDs were tested at a range of concentrations that were as close as possible to75
clinically relevant serum concentration (i.e.  phenytoin (5-40 , Gallagher and Sheehy,76
2000); topiramate (5- 40 , Hu et al., 2013); levetiracetam (5-40 , Bobustuc et al.,77
2010), lamotrigine (2.5-20 g/mL, Johannessen and Tomson, 2006) and carbamazepine (5-4078
, Gao and Chuang, 1991) (all from Sigma-Aldrich, UK). AEDs were solubilized in79
DMSO and stored as 2000-fold stock solutions.80
81
2.2 Western blotting82
Human foetal hFOB1.19 osteoprogenitor cells (hFOBs) were cultured as described83
previously (Humphrey et al., 2013). After establishing that parallel differentiated cultures84
were producing and mineralising a matrix in culture (Supplementary Figure 1), the hFOBs85
were treated with vehicle control (i.e. DMSO) or AEDs. Triplicate cultures of control and86
AED-treated hFOBs were harvested by trypsination after 24 hours of treatment and analysed87
by western blotting using an antibody against osteonectin (Santa Cruz Biotechnology), as88
described previously (Fuller et al., 2010).89
90
2.3 Immunofluorescence91
hFOBs were grown on coverslips, as described previously (Humphrey et al., 2013).92
For detection of collagen I, the coverslips were incubated with a pro-collagen I antibody93
(developed by McDonald, JA and obtained from the Developmental Studies Hybridoma Bank94
developed under the auspices of the NICHD, The University of Iowa, Department of Biology,95
Iowa City, IA 52242), as described previously (Fuller et al., 2010). Sequential scans were96
performed with a Leica TCS SP5 confocal microscope with a 40× objective. To reduce97
operator bias a fixed laser intensity was used for all image acquisition and images were only98
acquired from fields with even DAPI staining. To reduce edge effects only the inner two-99
5thirds of the coverslip were analysed. Immunofluorescence intensity was quantified using100
Image J software and normalised to DAPI intensity to account for variations in cell number.101
Statistical analysis was performed using a one-way analysis of variance (ANOVA), followed102
by c test.103
104
2.5 Gene expression105
hFOBs were cultured and treated with AEDs, as described for western blot analysis.106
RNA was extracted from triplicate pellets of control, valproate-treated and phenytoin-treated107
cells after 8 and 24 hours of treatment, using an RNAeasy kit (Qiagen). RNA (0.5 g) was108
reverse transcribed using the high capacity cDNA archive kit (Applied Biosystems)109
110
ACTB and GAPDH genes was performed using previously validated primers (Supplementary111
Table 1) and SYBR green master mix with the ABI 7500 real time PCR machine.112
113
Schmittgen, 2001), using the mean from the two endogenous reference genes, GAPDH and114
ACTB.115
116
117
3. Results118
119
3.1 Phenytoin treatment of hFOB cells results in a decrease in pro-collagen I120
immunoreactivity.121
Pre-differentiation hFOB cells were grown with or without AEDs at clinically122
relevant doses. After 24 hours treatment with phenytoin, pro-collagen I immunoreactivity123
was significantly decreased in a dose-dependent manner, with a maximum of 48% reduction124
6with a 20 g/mL dose (p=0.037) (Figure 1a and 1b). This statistically significant decrease is125
identical to the decrease observed after a 24 hour treatment of hFOBs with a clinically-126
relevant concentration of valproate (Humphrey et al., 2013). Collagen I gene expression127
levels were unaffected, suggesting that phenytoin alters pro-collagen I protein production or128
turnover (Figure 1c). We were unable to detect a statistically significant decrease in collagen129
I following treatment with topiramate, levetiracetam, lamotrigine or carbamazepine (data not130
shown). It was not possible to reliably quantify the effects of AEDs on pro-collagen I levels131
in post-differentiation hFOB cultures because the high density of cells obtained after132
differentiation prevents reliable quantification by immunofluorescence. However, a similar133
trend was evident by qualitative assessment of phenytoin-treated post-differentiation cells134
(Supplementary Figure 2).135
136
3.2 Phenytoin treatment of hFOB cells causes a dose-dependent change in the137
electrophoretic mobility of osteonectin.138
Unlike previous observations with valproate (Humphrey et al., 2013), treatment of139
hFOB cells with other commonly used AEDs did not appear to reduce the levels of140
osteonectin protein following treatment for 8 or 24 hours (as determined by western blot141
analysis) (Figure 2a). After 24 hours of incubation with phenytoin, however, a small but clear142
shift in apparent molecular weight of osteonectin was detectable by western blot in treated143
hFOB cell extracts (Figure 2b). The approximate 2-3kDa difference in electrophoretic144
mobility was evident following treatment with as little as 5 µg/mL of phenytoin and this145
change was not apparent following treatment with the other AEDs (Figure 2a). Neither146
protein (Figure 2b) nor gene expression levels of osteonectin were altered following147
treatment with phenytoin (Figure 2c).148
149
74. Discussion150
In this study we have demonstrated that, like valproate (Humphrey et al., 2013),151
phenytoin treatment of osteoblast-like cells with a clinically relevant dose results in a152
reduction of pro-collagen I protein. Despite the profound effect of valproate and phenytoin on153
pro-collagen I protein production, neither drug appeared to alter the expression levels of the154
collagen I gene (Figure 1c). Taken together, these results suggest that phenytoin, like155
valproate, appears to have a direct-effect on osteoblast-like cells by causing them to produce156
lower amounts of collagen I protein. It seems highly probable that this would have a157
detrimental effect on the bone forming ability of these cells since osteogenesis imperfecta, the158
is caused, in most cases, by mutations in collagen I chains (Rauch and159
Glorieux, 2004).160
None of the other AED compounds tested appeared to alter pro-collagen I protein161
levels. It is important to acknowledge, however, that some AEDs may require conversion to162
active metabolites in vivo, and it is not known whether osteoblast-like cells have the163
capability to do this.164
Unlike valproate (Humphrey et al., 2013), none of the other AEDs tested in this study165
caused a reduction in osteonectin protein levels in osteoblast-like cells, suggesting that the166
mechanism by which this occurs is not common to all AEDs. Interestingly though, treatment167
with phenytoin did alter the electrophoretic mobility of osteonectin in SDS-PAGE gels when168
compared to control-treated cells. Since protein levels were unaltered, the most likely169
explanation for the shift in electrophoretic mobility is a change in the glycosylation of170
osteonectin. Osteonectin exists as isoforms of various molecular weights, attributed to171
differences in glycosylation patterns (Kelm and Mann, 1991), each with different functions172
and varying affinities for collagen binding (Kaufmann et al., 2004). It seems highly likely,173
therefore, that alterations in the glycosylation pattern of osteonectin would affect its ability to174
8bind to collagen; thus influencing cellular ability to produce normal bone. This may explain a175
mechanism by which long-term phenytoin treatment can lead to bone weakness (reviewed in176
detail by Nakken and Taubøll (2010) and Lee et al., 2010), especially since two unrelated177
cases of osteogenesis imperfecta with a severe bone fragility were caused by rare178
homozygous mutations affecting the collagen I binding region of osteonectin (Mendoza-179
Londono et al., 2015).180
In summary, the findings in this study suggest that, as with valproate, perturbation of181
the important bone proteins, collagen I and osteonectin, could be one of the mechanisms that182
lead to bone loss following long-term treatment with phenytoin. The findings presented here183
provide a possible future direction for research focusing on the effects of AEDs on bone184
metabolism in-vivo.185
186
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Figure Legends277
278
Figure 1. Pro-collagen I protein, but not gene expression levels, is reduced in osteoblast-like279
cells after treatment with phenytoin. Acetone/methanol fixed cells were incubated with the280
anti-pro-collagen I monoclonal antibody (M-38) and visualised using a goat anti-mouse281
ALEXA 488. Bar = 100µm. Ten fields of view were chosen at random from each slide using282
DAPI view to avoid bias and include at least 200 cells over 10 images. The integrated density283
for each confocal microscope image was measured using ImageJ software and normalised to284
DAPI staining for each image. A representative image (A) and quantitative measurements285
from the dose response of phenytoin (PHT) on collagen protein (B) are shown. Collagen I286
gene expression was measured in cells treated with valproate (VPA) or PHT for 8 or 24hrs.287
No significant change in gene expression could be detected with either AED (C).288
289
Figure 2. Of the AEDs tested, only valproate reduced the levels of osteonectin protein in290
osteoblast-like cells. Protein extracts from differentiated osteoblast-like cells treated with291
carbamazepine (CBX), lamotrigine (LAM), with levetiracetam (LEV), topiramate (TOP) and292
valproate (VPA) were subjected to SDS-PAGE and transferred to nitrocellulose by293
electroblotting. The blots were probed with antibodies against osteonectin (SPARC, BM-40).294
Total protein staining with Ponceau S was used as a loading control. After visualization using295
a chemiluminescent system, the integrated density of the bands for osteonectin and ponceau S296
were measured using ImageJ software (A). A dose-dependent change in the electrophoretic297
13
mobility of osteonectin was evident, following treatment when treated with PHT (B). Neither298
VPA nor PHT had any effect on the gene expression levels of osteonectin (C).299
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